ASTRAZENECA PLC

AstraZeneca PLC reports a 11.7% surge in revenue to $14.457 billion in Q2 2025, driven by strategic collaborations and regulatory milestones in its oncology, cardiovascular, and respiratory therapeutic areas.

AstraZeneca PLC announces promising trial results and strategic partnerships, including successful breast cancer and gastric cancer treatments, and a new precision medicine partnership with Danaher Corporation.

AstraZeneca PLC kicked off 2025 with strong financial results, including a 7% increase in product revenue, and strategic collaborations that position the company for future success.